177Lu-DOTATATE in older patients with metastatic neuroendocrine tumours: safety, efficacy and health-related quality of life.

Luohai ChenShaunak NavalkissoorAnn-Marie QuigleyGopinath GnanasegaranDalvinder MandairChristos ToumpanakisMartyn E CaplinAimee R Hayes

Published in: European journal of nuclear medicine and molecular imaging (2021)

Patients ≥70 years of age with advanced NET treated with 177Lu-DOTATATE have efficacy and toxicity profiles similar to the wider NET population, without deterioration of HRQoL.

Keyphrases

pet ct
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
neuroendocrine tumors
peritoneal dialysis
patient reported outcomes
community dwelling